EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease

David Z I Cherney, Nicolas Belmar, Petter Bjornstad, Milenta M Chacko, Thomas P Gunnarsson, Jeffrey B Hodgin, Matthias Kretzler, Menno Pruijm iD, Philip A Schytz, Katherine R Tuttle iD

Nephrology Dialysis Transplantation · 30.10.2025 · 40 (11) · 2182-2192

DOI: 10.1093/ndt/gfaf114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 03.07.2025. Verfasst von David Z I Cherney und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces the risk of major kidney, cardiovascular and mortality outcomes in people with T2D and CKD, but the mechanism of action remains unclear.

Methods

The REMODEL trial (NCT04865770) is a 52-week placebo-controlled, double-blind, parallel-group, randomized trial in adults with T2D and CKD. Inclusion criteria include haemoglobin A1c (HbA1c) ≤9%, estimated glomerular filtration rate (eGFR) ≥30–≤75 ml/min/1.73 m2 and urine albumin:creatinine ratio (UACR) ≥20–<5000 mg/g. The co-primary outcomes were magnetic resonance imaging (MRI) based, including change in kidney oxygenation, perfusion and inflammation. Secondary outcomes include change from baseline in creatine clearance rate, urinary sodium excretion, albumin excretion rate and kidney fibrosis and blood flow parameters measured by MRI. A subgroup had kidney biopsies at baseline and at the end of the treatment for tissue-based interrogation, including single nucleus and spatial transcriptomics, pathology and advanced histological assessment.

Results

Across eight countries, 106 participants (n = 33, biopsy subgroup) were enrolled. The mean age was 65.3 years [standard deviation (SD) 9.9] at baseline with HbA1c of 7.1% (SD 0.9), creatinine-based eGFR of 51.1 ml/min/1.73 m2 (SD 10.4) and median UACR of 187.3 mg/g (interquartile range 60.5–546.4). Renin–angiotensin system inhibitor use was 98.1% and sodium–glucose co-transporter 2 inhibitor use was 38.7%. In the kidney biopsy subgroup, baseline characteristics were like those of the full population. Histological analysis of kidney tissues revealed 17 participants with primarily diabetic nephropathy, 6 participants with primarily vascular features, 9 with mixed diabetic nephropathy and vascular characteristics and 1 with membranous nephropathy.

Conclusion

The REMODEL trial leverages multipronged approaches to investigate the kidney-specific effects and underlying mechanisms of semaglutide in a representative population of people with T2D and CKD, which supports the generalizability and clinical relevance of the findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesHypoglycemic AgentsRenal Insufficiency, ChronicAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodFollow-Up StudiesGlomerular Filtration RateGlycated HemoglobinPrognosisClinical Trials, Phase III as TopicMulticenter Studies as TopicRandomized Controlled Trials as TopicGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

functional magnetic resonance imaginggene expressionincretin therapykidneynutrient-stimulated hormone (NuSH) therapy

Substanzen

Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, and Division of Endocrinology, Department of Pediatrics, University of Washington, Seattle, WA, USA.
  • Division of Renal Diseases and Hypertension, Department of Medicine, Section of Pediatric Endocrinology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Novo Nordisk GBS India, Bangalore, India.
  • Department of Pathology and Clinical Laboratories, University of Michigan, Ann Arbor, MI, USA.

ORCID-Profile: Menno Pruijm, Katherine R Tuttle

Förderung

  • NIDDK NIH HHS
  • Novo Nordisk

Zitieren

APA

Cherney, D. Z. I., Belmar, N., Bjornstad, P., Chacko, M. M., Gunnarsson, T. P., Hodgin, J. B., Kretzler, M., Pruijm, M., Schytz, P. A., & Tuttle, K. R. (2025). Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 40(11), 2182-2192. https://doi.org/10.1093/ndt/gfaf114

Vancouver

Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, et al. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. 2025;40(11):2182-2192. doi:10.1093/ndt/gfaf114

BibTeX
@article{Cherney2025,
  author = {Cherney, David Z I and Belmar, Nicolas and Bjornstad, Petter and Chacko, Milenta M and Gunnarsson, Thomas P and Hodgin, Jeffrey B and Kretzler, Matthias and Pruijm, Menno and Schytz, Philip A and Tuttle, Katherine R},
  title = {Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {11},
  pages = {2182--2192},
  doi = {10.1093/ndt/gfaf114}
}
Kostenlos starten →